Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Endocrinology | Pediatrics/Neonatology
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Norditropin (somatropin (rDNA origin) for injection)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Novo Nordisk
Approval Status: Approved February 1997
Treatment Area: Growth failure in children
Norditropin is indicated for the long-term treatment of children
who have growth failure due to inadequate secretion of endogenous
(pituitary gland produced) growth hormone.
Human growth hormone is responsible for stimulating normal
skeletal, connective tissue, muscle and organ growth in children
and adolescents. It is also active in normal protein, carbohydrate
and fat metabolism. If the amount of growth hormone production by
the body is insufficient, short stature, reduced muscle and soft
tissue mass and altered nutrient metabolism result. Such problems
significantly impact an individual’s physical function throughout
life, if not treated appropriately.